The current trend in the treatment of patients with advanced ccRCC is the continued development of clinical combinations of biologics that target the upregulated pro-angiogenic pathways with immune checkpoint inhibitors and mTOR inhibitors. Here, MTOR is linked to nonpapillary renal cell carcinoma.